Cabaletta Bio Inc. Company Profile
NASDAQ: CABAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Cabaletta Bio at a glance
Cabaletta Bio Inc. (NASDAQ: CABA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Philadelphia, PA. Cabaletta Bio is led by Dr. Steven A. Nichtberger M.D. and employs about 154 people. The company's shares have traded publicly since 2019.
At a market capitalization of $201.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001759138, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Cabaletta Bio do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Cabaletta Bio Inc.
- Ticker
- NASDAQ: CABA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Steven A. Nichtberger M.D.
- Employees
- 154
- Headquarters
- 2929 Arch Street, Philadelphia, PA, United States
- Phone
- 267 759 3100
- Website
- cabalettabio.com
- IPO year
- 2019
- Market cap
- $201.94M
- SEC CIK
- 0001759138
- Latest annual report
- 10-K · Mar 23, 2026
Companies similar to Cabaletta Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs CABA |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs CABA |
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs CABA |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs CABA |
| IKTInhibikase Therapeutics Inc. | 1.32 | +1.54% | $185.16M | vs CABA |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs CABA |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs CABA |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs CABA |